Johnson & Johnson reports Q4 and Full-Year 2025 results
View original at finance.yahoo.comJohnson & Johnson reports Q4 and Full-Year 2025 results 2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisiti…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
2026 adjusted operational EPS guidance of $11.28-$11.48 with midpoint of $11.38 representing 5.5% growth
80% confidence2026 adjusted EPS guidance of $11.43-$11.63 with midpoint of $11.53 representing 6.9% growth
80% confidenceTREMFYA is the only IL-23 inhibitor proven to inhibit structural joint damage in active psoriatic arthritis
80% confidenceINLEXZO achieved 74% disease-free survival at one year in BCG-unresponsive high-risk papillary-only NMIBC
80% confidenceDARZALEX FASPRO is the first/only FDA-approved treatment for high-risk smoldering multiple myeloma
80% confidence2026 adjusted operational sales growth guidance of 5.4%-6.4% with midpoint of 5.9%
80% confidenceRYBREVANT FASPRO + LAZCLUZE has the shortest administration time for first-line combination regimen
80% confidence2026 operational sales guidance of $99.5B-$100.5B with midpoint of $100.0B representing 6.2% growth
80% confidenceTECVAYLI + DARZALEX FASPRO demonstrated superior PFS and OS vs. standard of care in second-line multiple myeloma
80% confidenceNipocalimab is the first/only investigational FcRn blocker showing potential to reduce SLE activity in Phase 2
80% confidenceAKEEGA demonstrates 54% reduction in disease progression in BRCA2-mutated metastatic castration-sensitive prostate cancer
80% confidence2026 reported sales guidance of $100.0B-$101.0B with midpoint of $100.5B representing 6.7% growth
80% confidenceSubcutaneous amivantamab achieved 45% overall response rate with 7.2-month median duration in recurrent/metastatic head and neck cancer
80% confidence